Actualités et vidéos - ONCOSEC MEDICAL INC.

OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules PR Newswire EWING, N.J. and SAN DIEGO, May 18, 2023 EWING, N.J. and SAN DIEGO , May 18, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient's immune system to target cancer cells and eradicate disease, today announced the closing of its...

OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules PR Newswire EWING, N.J. and SAN DIEGO, May 16, 2023 EWING, N.J. and SAN DIEGO , May 16, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient's immune system to target cancer cells and eradicate disease, today announced that it has entered into a...

OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program PR Newswire EWING, N.J. and SAN DIEGO, May 16, 2023 EWING, N.J. and SAN DIEGO , May 16, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the Company or OncoSec), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient's immune system to target cancer cells and eradicate disease, today announced a Type C meeting held with the US Food...

OncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Program PR Newswire EWING, N.J. and SAN DIEGO, April 27, 2023 EWING, N.J. and SAN DIEGO , April 27, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the Company or OncoSec), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient's immune system to target cancer...

OncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules PR Newswire EWING, N.J. and SAN DIEGO, April 11, 2023 EWING, N.J. and SAN DIEGO , April 11, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient's immune system to target cancer cells and eradicate disease, today announced the closing of its...

OncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules PR Newswire EWING, N.J. and SAN DIEGO, April 10, 2023 EWING, N.J. and SAN DIEGO , April 10, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient's immune system to target cancer cells and eradicate disease, today announced that it has entered into a...

OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment PR Newswire EWING, N.J. and SAN DIEGO, April 3, 2023 EWING, N.J. and SAN DIEGO , April 3, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the Company or OncoSec), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient's immune system to...

Thinking about buying stock in OncoSec Medical, Diversified Healthcare, Cardio Diagnostics, Plug Power, or Macy's? PR Newswire NEW YORK, March 2, 2023 NEW YORK , March 2, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ONCS , DHC , CDIO , PLUG, and M . To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ONCS:...

OncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022 PR Newswire PENNINGTON, N.J. and SAN DIEGO, Dec. 5, 2022 PENNINGTON, N.J. and SAN DIEGO , Dec. 5, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the patient's own immune system to target and eradicate cancer, today announced that Robert Arch , Ph.D., President...

OncoSec Announces Pricing of $3.5 Million Public Offering PR Newswire PENNINGTON, N.J. and SAN DIEGO, Nov. 30, 2022 PENNINGTON, N.J. and SAN DIEGO , Nov. 30, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the patient's own immune system to target and eradicate cancer, today announced the pricing of its "reasonable best efforts" public offering of...

Thinking about buying stock in Apollo Endosurgery, OncoSec Medical, Cosmos Holdings, Zhihu, or Bilibili? PR Newswire NEW YORK, Nov. 29, 2022 NEW YORK , Nov. 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APEN, ONCS, COSM, ZH, and BILI. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. APEN:...

OncoSec presents encouraging early data with TAVO™-EP combined with nivolumab (Opdivo®) in neoadjuvant melanoma PR Newswire PENNINGTON, N.J. and SAN DIEGO, Nov. 15, 2022 PENNINGTON, N.J. and SAN DIEGO , Nov. 15, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical stage biotechnology company developing intratumoral immunotherapies that stimulate the patient's immune system to target cancer cells and eradicate disease, today announced early...

OncoSec Announces Positive Clinical Data of the KEYNOTE-695 Trial Assessing TAVO-EP in Combination with Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment PR Newswire PENNINGTON, N.J. and SAN DIEGO, Nov. 11, 2022 PENNINGTON, N.J. and SAN DIEGO , Nov. 11, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral immunotherapies that stimulate the...

OncoSec Announces Reverse Stock Split PR Newswire PENNINGTON, N.J. and SAN DIEGO, Nov. 8, 2022 PENNINGTON, N.J. and SAN DIEGO , Nov. 8, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the patient's own immune system to target and eradicate cancer, today announced it intends to effect a 1-for-22 reverse split of its issued and outstanding common...

OncoSec Announces Pipeline Prioritization and Workforce Reduction PR Newswire PENNINGTON, N.J. and SAN DIEGO, Oct. 4, 2022 PENNINGTON, N.J. and SAN DIEGO , Oct. 4, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the patient's own immune system to target and eradicate cancer, today announced a corporate restructuring intended to prioritize...

Novel pre-clinical results regarding OncoSec's intratumoral electroporation platform were highlighted as Editor's Pick in Molecular Cancer Research PR Newswire PENNINGTON, N.J. and SAN DIEGO, June 24, 2022 Results demonstrate novel synergistic effects of IL-12 and T cell receptor signaling in anti-tumor immunity PENNINGTON, N.J. and SAN DIEGO , June 24, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on...

OncoSec Receives Triple Negative Breast Cancer Foundation's Vanguard Award for Excellence in Oncology Research PR Newswire PENNINGTON, N.J. and SAN DIEGO, May 23, 2022 PENNINGTON, N.J. and SAN DIEGO , May 23, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec") today announced that it is the recipient of the 2022 Vanguard Award presented by the Triple Negative Breast Cancer (TNBC) Foundation. OncoSec's Head of Patient Advocacy, Kimberly Irvine , will...

OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer PR Newswire PENNINGTON, N.J. and SAN DIEGO, April 29, 2022 PENNINGTON, N.J. and SAN DIEGO , April 29, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer, today announced the appointment of Robert H. Arch , Ph.D., as President...

OncoSec Announces Appointment of George Chi as Chief Financial Officer PR Newswire PENNINGTON, N.J. and SAN DIEGO, Feb. 22, 2022 PENNINGTON, N.J. and SAN DIEGO , Feb. 22, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer, today announced the appointment of George Chi as Chief Financial Officer. Mr....

OncoSec Announces Changes to its Board of Directors PR Newswire PENNINGTON, N.J. and SAN DIEGO, Dec. 17, 2021 PENNINGTON, N.J. and SAN DIEGO , Dec. 17, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer, today announced that Margaret Dalesandro , Ph.D., Chair of the Board of Directors...